Clinical trial
Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis…
NCT00228163 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00228163 |
|---|---|
| Title | Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses |
| Official title | Extension of Protocol HMR1726D/2001, A Phase II Study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | teriflunomide (HMR1726) |
| Enrollment | 147 |
| Start date | Jan 1, 2002 |
| Primary completion | Jan 1, 2015 |
| Completion | Jan 1, 2015 |
| First posted | Sep 28, 2005 |
| Last update posted | Mar 25, 2015 |
| Countries | Canada, France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: